#United States #New York #Gross Law Firm #REGENXBIO #RGX-111

REGENXBIO Inc. Shareholder Alert: Actionable Insights

In a significant development for investors of REGENXBIO Inc. (NASDAQ: RGNX), The Gross Law Firm has released a crucial alert urging shareholders to pay attention to the ongoing securities class action lawsuit. This serves as a pivotal moment for anyone involved with REGENXBIO, particularly those who have held shares between February 9, 2022, and January 27, 2026.

Key Details of the Lawsuit

The lawsuit alleges that REGENXBIO misled investors regarding the development and commercialization of its gene therapy candidate, RGX-111, which aims to treat serious conditions such as Mucopolysaccharidosis Type I, commonly known as Hurler syndrome. The complaint claims that while the company communicated optimism about RGX-111's future success, it simultaneously concealed significant adverse facts about the trial's efficacy and safety.

On January 28, 2026, following the announcement that the FDA had placed a clinical hold on RGX-111 due to the discovery of a CNS tumor in a trial participant, REGENXBIO's stock price plummeted by 17.8%, highlighting the severe impact of these misleading communications. The stock fell from a closing price of $13.41 to $11.01 within just one trading day, causing significant losses for shareholders.

Important Dates and Deadlines

Shareholders are urged to act quickly as the deadline to register for participation as a lead plaintiff in this class action lawsuit is set for April 14, 2026. It's crucial for those who purchased RGNX shares during the specified class period to enroll to ensure they receive updates and protect their rights as investors.

Steps to Take

To register, investors can provide their information through the Gross Law Firm's designated portal. Notably, becoming a lead plaintiff is not a prerequisite for participating in any potential recovery from this lawsuit. Additionally, shareholders will be enrolled in a portfolio monitoring system to receive ongoing updates about the case’s progression.

Why Choose The Gross Law Firm?

The Gross Law Firm stands out as a nationally recognized entity in defending the rights of investors against deceit and fraud. Their commitment extends to promoting ethical business practices and protecting shareholders from false claims that artificially inflate stock prices. The firm is dedicated to seeking justice for those impacted by misleading information disseminated by companies.

With the situation developing rapidly, affected shareholders must keep themselves informed and prepared to take action as the lawsuit unfolds. Those interested should act without delay to avoid missing out on their chance for potential recovery.

Contact Information

For further details or inquiries, shareholders can reach the Gross Law Firm at:

• - Address: 15 West 38th Street, 12th Floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

Staying informed is essential for shareholders of REGENXBIO Inc., and acting swiftly can ensure protection of their investment rights in this pivotal case.